Patients who underwent ACL repair had similar functional outcomes but higher failure rates at 5 years compared with patients who underwent ACL reconstruction, according to recently published data.
“[The graft failure rate] at 2 years is acceptable, but at 5 years, it is absolutely a shame to have this result for a younger population,” Bertrand Sonnery-Cottet, MD, PhD, an orthopedic surgical consultant at the Centre Orthopédique Santy in Lyon, France, told Healio.
Researchers analyzed the same patients from a 2022 study by Sonnery-Cottet and colleagues that evaluated the clinical and functional

Young adults with cardiovascular-kidney-metabolic syndrome may experience early carotid arterial injury vs. people without risk factors for adverse cardiometabolic health, researchers reported.
People as young as age 22 years with cardiovascular-kidney-metabolic (CKM) syndrome may experience early progression of arterial injury and have more CVD risk factors, according to data published in Circulation: Population Health and Outcomes.
“We know that risk factors like elevated BP, adverse blood lipids and elevated blood glucose that accumulate over the life course are strongly associated

A machine learning tool helped to identify patients at risk for severe AKI, but early nephrology consultations did not prevent increases in serum creatinine among hospitalized adults without AKI.
The data were published in JAMA Network Open.
Few randomized clinical trials on AKI prevention have solely looked at patients before AKI onset, according to Jay L. Koyner, MD, professor of medicine in the section of nephrology at the University of Chicago, and colleagues. Thus, the researchers aimed to evaluate whether an early nephrology consultation, driven by a machine-learning AKI risk score

The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with fibrodysplasia ossificans progressiva, according to an industry press release.
Garetosmab-grts (Pasatru, Regeneron) is a monoclonal antibody administered through IV infusion. According to Regeneron, the therapy is the first approved by the FDA for reducing new heterotopic ossification lesions in fibrodysplasia ossificans progressiva, a rare condition in which lesions inhibit the function of muscles, tendons, ligaments and other connected tissues.
Approval of

Industry-sponsored dermatology trials had higher completion and publication rates than academic dermatology trials, according to a study published in the Journal of the American Academy of Dermatology.
Industry-sponsored trials were also completed in a shorter time, outpacing academic trials by 13 weeks (95% CI, 10-15), according to Rebecca I. Hartman, MD, MPH, FAAD, associate professor of dermatology at Harvard Medical School.
“These findings could be due to several different factors, which are unclear, such as differences in study design, funding and reporting bias,” Hartman told Healio.

During a Healio Community webinar, Majid Fotuhi, MD, PhD, shared his evidence-based methods for stimulating cognition and focusing on five modifiable factors to lower risk for Alzheimer’s disease.
These tips are featured in a 12-week plan for improving brain health in his book, The Invincible Brain: The Clinically Proven Plan to Age-Proof Your Brain and Stay Sharp for Life, Healio Community’s book club pick for April.
According to Hansa Bhargava, MD, chief clinical strategy and innovation officer at Healio, 7.4 million Americans aged 65 years and older have Alzheimer’s disease as of this year,

Communication and collaboration between juvenile- and adult-care rheumatologists will be essential in the face of workforce shortages across pediatric rheumatology, according to a presenter.
“I’m here to direct your gaze toward a small but mighty sector of our field,” Mia Chandler, MD, MPH, an assistant professor of rheumatology and pediatrics at the Wake Forest University School of Medicine, said of pediatric rheumatology in her keynote address at the Association of Women in Rheumatology (AWIR) annual conference.
Chandler highlighted the particular challenges pediatric

In this video, Cristian Lasagna-Reeves, PhD, spoke with Healio about how the Alzheimer’s Association International Conference has evolved in recent years.
“This meeting is a little bit more clinical,” Lasagna-Reeves, an associate professor in the department of neurology at Baylor College of Medicine, said. “Before, it was really basic science.”
He explained that advancements in therapies targeting tau and amyloid have provided potential options for Alzheimer’s disease.
“It gives me hope in the meeting, seeing that each time there is more clinical research — like maybe 20 years ago, it was almost

In this video, Cristian Lasagna-Reeves, PhD, spoke with Healio about results from the phase 2 CELIA trial presented at this year’s Alzheimer’s Association International Conference.
The trial assessed the use of diranersen (BIIB080, Biogen) to reduce tau production in patients diagnosed with mild cognitive impairment or mild Alzheimer’s disease.
“I don’t want to say positive, but really promising results,” Lasagna-Reeves, an associate professor in the department of neurology at Baylor College of Medicine, said, emphasizing the need for further research in a phase 3 trial.

Just 53% of Maine households on well water have tested for arsenic. A state aid program has treated 57 homes as filter costs climb.